Form 4: Aldeyra Therapeutics Director Acquires Stock Options

Nancy Miller-Rich, a director at Aldeyra Therapeutics, acquired stock options on June 4, 2024.

Summary

• On June 4, 2024, Nancy Miller-Rich, a director of Aldeyra Therapeutics, acquired stock options.
• She acquired 40,282 stock options exercisable at $4.09, vesting one year from the grant date, contingent on continuous service as a board member.
• Additionally, she acquired 1,736 stock options exercisable at $4.09, vesting one year from the grant date, contingent on continuous service as a member of the Compensation Committee.
• The expiration date for both sets of options is June 3, 2034.
• Following the transaction, Miller-Rich directly owns 40,282 and 1,736 stock options.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document simply reports the acquisition of stock options by a company director, which is a routine event.

Positives

• The acquisition of stock options by a director may signal confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of regulatory compliance for publicly traded companies and their insiders. They provide transparency into the transactions of company directors and officers.

Stakeholder Impact

• The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with those of the shareholders.

Key Dates